- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05224778
DMCRN-02-001: DM1에서 소아 종점 평가 (ASPIRE-DM1)
DM1(ASPIRE-DM1)에서 소아 종점 평가
The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and develop biomarkers for the condition.
연구 개요
상태
정황
상세 설명
Myotonic dystrophy type-1 (DM1) is an autosomal dominant disorder caused by a toxic CTG repeat expansion in the 3'UTR of the DMPK gene. DM1 is the most common adult-onset muscular dystrophy, with an overall prevalence of 1:8000. In approximately 10-20% of individuals with DM1, the onset of symptoms occurs at birth, which is known as congenital myotonic dystrophy (CDM).
Previous studies have enrolled a very limited number of children with CDM.
The rationale for this study is to include a larger population of patients with CDM in order to determine developmental milestones, measures of physical and cognitive function and quality of life, and correlate functional outcome measures with potential biomarkers in CDM .
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Ruby Langeslay
- 전화번호: 804-828-8481
- 이메일: ruby.langeslay@vcuhealth.org
연구 연락처 백업
- 이름: Jennifer Raymond
- 전화번호: 804-828-6318
- 이메일: jennifer.raymond@vcuhealth.org
연구 장소
-
-
California
-
Los Angeles, California, 미국, 90095
- 모병
- University of California, Los Angeles
-
연락하다:
- Merve Kaleli
- 이메일: MKaleli@mednet.ucla.edu
-
수석 연구원:
- Perry Shieh, MD, PhD
-
연락하다:
- Dennis Fernando
- 전화번호: 310-825-3264
- 이메일: DeFernando@mednet.ucla.edu
-
-
Kansas
-
Fairway, Kansas, 미국, 66205
- 모병
- University of Kansas Medical Center
-
수석 연구원:
- Jeffrey Statland, MD
-
연락하다:
- Michaela Walker
- 이메일: mwalker20@kumc.edu
-
연락하다:
- Cassidy Nelson
- 이메일: cnelson15@kumc.edu
-
-
New York
-
Rochester, New York, 미국, 14642
- 모병
- University of Rochester Medical Center
-
연락하다:
- Jim Hilbert
- 이메일: james_hilbert@urmc.rochester.edu
-
연락하다:
- Jeanne Dekdebrun
- 이메일: jeanne_dekdebrun@urmc.rochester.edu
-
수석 연구원:
- Bohoon Lee, MD
-
-
Virginia
-
Richmond, Virginia, 미국, 23298
- 모병
- Virginia Commonwealth University
-
연락하다:
- Shantel Kyles
- 이메일: shantel.brown@vcuhealth.org
-
수석 연구원:
- Nicholas E. Johnson, MD
-
연락하다:
- Jodie Howell
- 이메일: jodie.howell@vcuhealth.org
-
-
-
-
-
Milan, 이탈리아, 20162
- 모병
- Centro Clinico NeMO
-
연락하다:
- Michela Nani
- 이메일: michela.nani@centrocliniconemo.it
-
연락하다:
- Luca Mauro
- 이메일: luca.mauro@centrocliniconemo.it
-
수석 연구원:
- Valeria Sansone, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
30 children with CDM
설명
Inclusion Criteria:
- Age neonate to 3 years 11 months at enrollment.
- A diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
- Guardian is willing and able to sign consent and follow study procedures
Exclusion Criteria:
- Any other non-DM1 illness that would interfere with the ability or results of the study in the opinion of the site investigator
- Significant trauma within one month
- Internal metal or devices (exclusion for DEXA component)
- History of bleeding disorder or platelet count <50,000
- History of reaction to local anesthetic
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
|---|
|
Congenital Myotonic Dystrophy (CDM)
CDM group includes those aged neonate to 3 years, 11 months at enrollment. Individuals must have a diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500). |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
To evaluate motor milestone attainment in individuals with CDM and ChDM and compare to typically developing children
기간: Through study completion at 18 months
|
Milestone Assessment using Peabody definitions: This survey would ask parents to assess the age of motor milestones in days, months of infant age. Birth history, including prematurity, ventilatory status, and feeding problems would also be collected on the CRF. Feeding and ventilatory support, as well as height and weight will be collected at each study visit. |
Through study completion at 18 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Dysarthria Assessment
기간: Through study completion at 18 months
|
A blinded, standardized video assessment tabulating language milestones by a trained rater will be conducted at each visit. |
Through study completion at 18 months
|
|
Vineland
기간: Through study completion at 18 months
|
The Vineland will be administered by an interviewer to ensure standardized intake of data. This assessment will capture the adaptive function, including gross motor and fine motor, as reported by the parent proxy. |
Through study completion at 18 months
|
|
CCMDHI
기간: Through study completion at 18 months
|
The congenital and childhood myotonic dystrophy health index is a disease specific patient or proxy reported outcome measure specific to these conditions. The current study will utilize the proxy version. |
Through study completion at 18 months
|
|
Domain Delta
기간: Through study completion at 18 months
|
This assessment asks parents for global impression of change related to the baseline visit and will be used as an anchoring measure for the statistical analyses. |
Through study completion at 18 months
|
|
Gross Motor Function Measure (GMFM-88)
기간: Through study completion 18 months
|
The GMFM assesses functional abilities like lying/rolling, sitting, crawling/kneeling, standing, and walking, running, and jumping. |
Through study completion 18 months
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Correlate the functional outcome measures with potential biomarkers in CDM.
기간: Baseline
|
Fine needle muscle biopsy:On the baseline visit, a fine needle aspirate will be performed. Biopsy will only be peformed once to minimize the risk. The procedure will be performed with local anesthesia (1% lidocaine without epinephrine and free of preservatives) of the vastus lateralis. Following lidocaine injection, a fine needle will be used to aspirate the quadriceps muscle to obtain a total of one aspirate. The aspirate will be flash frozen in liquid nitrogen. A similar procedure has been performed on adults with DM1, and the average biopsy yields sufficient tissue for RNA-Seq analysis. |
Baseline
|
|
Blood Sampling
기간: Baseline, month 12, month 18
|
DNA and RNA samples will be processed by Virginia Commonwealth University. |
Baseline, month 12, month 18
|
|
Muscle mass, DEXA
기간: Baseline, month 12, month 18
|
Lean muscle mass will be evaluated using serial DEXA scans as an exploratory endpoint. All sites will use a Hologic DEXA scanner. Investigators will evaluate whole body lean mass, left and right arm lean mass, and left and right leg lean mass. Particularly early in childhood, investigators would expect rapid changes in lean muscle mass. If there were a divergence between controls and subjects with CDM, this would provide evidence that CDM is a disorder of muscle maturity, as well as provide a potential biomarker. |
Baseline, month 12, month 18
|
|
World Health Organization (WHO) Motor Milestones
기간: Through study completion at 18 months
|
The WHO Motor Milestones is a set of 6 standardized motor milestones that include 1) Sitting without support, 2) Standing with assistance, 3) Hands-&-knees crawling, 4) Walking with assistance, 5) Standing alone, and 6) Walking alone. |
Through study completion at 18 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Nicholas E. Johnson, MD, Virginia Commonwealth University
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- HM20023386
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .